Go Against the Grain and Buy Molycorp (MCP) - Oracle Investment Research
Tweet Send to a FriendGet Alerts MCP Hot Sheet
Price: $7.22 --0%
Rating Summary:
5 Buy, 8 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 0 | Down: 1 | New: 6
Rating Summary:
5 Buy, 8 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 0 | Down: 1 | New: 6
Trade MCP Now!
Oracle Investment Research is going full out contrarian on Molycorp (NYSE: MCP).
Although shares are in a death spiral, Oracle is upgrading shares from Buy to Strong Buy with a price target of $50.00.
The firm notes that MCP is below the IPO price and below paid-in capital. MCP has raised a total of ~$2.3 billion, and at today's price shares are at a market cap of $1.1 billion.
They also note spot prices of REOs' are stable "and showing signs of a mild pick up." "With production quotas from China estimated to drop by 20% to 80kMT in 2013, timing of MCP to ramp up production is fortuitous."
"This raise, which we estimate to be the last, puts MCP in a comfortable cash position."
For an analyst ratings summary and ratings history on Molycorp click here. For more ratings news on Molycorp click here.
Shares of Molycorp are down 10 percent today after the capital raise and downgrade at Dahlman Rose.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Although shares are in a death spiral, Oracle is upgrading shares from Buy to Strong Buy with a price target of $50.00.
The firm notes that MCP is below the IPO price and below paid-in capital. MCP has raised a total of ~$2.3 billion, and at today's price shares are at a market cap of $1.1 billion.
They also note spot prices of REOs' are stable "and showing signs of a mild pick up." "With production quotas from China estimated to drop by 20% to 80kMT in 2013, timing of MCP to ramp up production is fortuitous."
"This raise, which we estimate to be the last, puts MCP in a comfortable cash position."
For an analyst ratings summary and ratings history on Molycorp click here. For more ratings news on Molycorp click here.
Shares of Molycorp are down 10 percent today after the capital raise and downgrade at Dahlman Rose.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Molycorp (MCP) Continues Recent Surge Higher; Fundamentals Come Into Play
- UPDATE: Cell Therapeutics (CTIC) on The Move
- 50-Day SMA Crossers 05/20: (ELN) (ACI) (AAPL) Above; (MRK) (TLAB) (CLSN) Below
Create E-mail Alert Related Categories
Trader Talk, Upgrades
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
